nodes	percent_of_prediction	percent_of_DWPC	metapath
Regorafenib—BRAF—bone cancer	0.318	0.494	CbGaD
Regorafenib—KIT—bone cancer	0.255	0.396	CbGaD
Regorafenib—CYP3A4—bone cancer	0.0707	0.11	CbGaD
Regorafenib—ABCG2—Carboplatin—bone cancer	0.0288	0.195	CbGbCtD
Regorafenib—ABCG2—Cisplatin—bone cancer	0.0246	0.166	CbGbCtD
Regorafenib—CYP2B6—Cisplatin—bone cancer	0.0173	0.117	CbGbCtD
Regorafenib—ABCG2—Doxorubicin—bone cancer	0.0165	0.111	CbGbCtD
Regorafenib—ABCG2—Methotrexate—bone cancer	0.016	0.108	CbGbCtD
Regorafenib—CYP2B6—Doxorubicin—bone cancer	0.0116	0.0783	CbGbCtD
Regorafenib—CYP2C9—Cisplatin—bone cancer	0.00915	0.0618	CbGbCtD
Regorafenib—ABCB1—Cisplatin—bone cancer	0.00888	0.0599	CbGbCtD
Regorafenib—ABCB1—Doxorubicin—bone cancer	0.00595	0.0402	CbGbCtD
Regorafenib—ABCB1—Methotrexate—bone cancer	0.00576	0.0389	CbGbCtD
Regorafenib—Posterior reversible encephalopathy syndrome—Cisplatin—bone cancer	0.00374	0.0705	CcSEcCtD
Regorafenib—CYP3A4—Doxorubicin—bone cancer	0.00357	0.0241	CbGbCtD
Regorafenib—FGFR2—skull—bone cancer	0.00235	0.109	CbGeAlD
Regorafenib—Sorafenib—BRAF—bone cancer	0.00234	0.494	CrCbGaD
Regorafenib—Sorafenib—KIT—bone cancer	0.00188	0.396	CrCbGaD
Regorafenib—KDR—hindlimb—bone cancer	0.0016	0.0743	CbGeAlD
Regorafenib—KDR—appendage—bone cancer	0.00137	0.0637	CbGeAlD
Regorafenib—Amylase increased—Cisplatin—bone cancer	0.00129	0.0243	CcSEcCtD
Regorafenib—Hypophosphataemia—Cisplatin—bone cancer	0.00106	0.0199	CcSEcCtD
Regorafenib—DDR2—connective tissue—bone cancer	0.000977	0.0454	CbGeAlD
Regorafenib—Hepatotoxicity—Cisplatin—bone cancer	0.000794	0.015	CcSEcCtD
Regorafenib—Infection—Carboplatin—bone cancer	0.000741	0.014	CcSEcCtD
Regorafenib—Liver injury—Cisplatin—bone cancer	0.000729	0.0138	CcSEcCtD
Regorafenib—DDR2—tendon—bone cancer	0.000671	0.0312	CbGeAlD
Regorafenib—Hyperuricaemia—Cisplatin—bone cancer	0.000661	0.0125	CcSEcCtD
Regorafenib—DDR2—spinal cord—bone cancer	0.000647	0.0301	CbGeAlD
Regorafenib—Pain—Carboplatin—bone cancer	0.000638	0.012	CcSEcCtD
Regorafenib—Blood uric acid increased—Cisplatin—bone cancer	0.000624	0.0118	CcSEcCtD
Regorafenib—Lymphopenia—Epirubicin—bone cancer	0.000615	0.0116	CcSEcCtD
Regorafenib—Mucosal inflammation—Methotrexate—bone cancer	0.000608	0.0115	CcSEcCtD
Regorafenib—Body temperature increased—Carboplatin—bone cancer	0.00059	0.0111	CcSEcCtD
Regorafenib—Lymphopenia—Doxorubicin—bone cancer	0.000569	0.0107	CcSEcCtD
Regorafenib—Mucosal inflammation—Epirubicin—bone cancer	0.000569	0.0107	CcSEcCtD
Regorafenib—Polyp—Methotrexate—bone cancer	0.000553	0.0104	CcSEcCtD
Regorafenib—Hypophosphataemia—Epirubicin—bone cancer	0.000542	0.0102	CcSEcCtD
Regorafenib—Mucosal inflammation—Doxorubicin—bone cancer	0.000526	0.00994	CcSEcCtD
Regorafenib—RET—connective tissue—bone cancer	0.000525	0.0244	CbGeAlD
Regorafenib—Sorafenib—CYP3A4—bone cancer	0.00052	0.11	CrCbGaD
Regorafenib—Nail disorder—Methotrexate—bone cancer	0.000519	0.00979	CcSEcCtD
Regorafenib—Polyp—Epirubicin—bone cancer	0.000518	0.00977	CcSEcCtD
Regorafenib—Cyst—Methotrexate—bone cancer	0.000503	0.0095	CcSEcCtD
Regorafenib—Hypophosphataemia—Doxorubicin—bone cancer	0.000501	0.00947	CcSEcCtD
Regorafenib—FGFR2—connective tissue—bone cancer	0.000499	0.0232	CbGeAlD
Regorafenib—ABL1—Idarubicin—Epirubicin—bone cancer	0.000497	0.173	CbGdCrCtD
Regorafenib—ABL1—Doxorubicin—Epirubicin—bone cancer	0.000497	0.173	CbGdCrCtD
Regorafenib—ABL1—Daunorubicin—Epirubicin—bone cancer	0.000497	0.173	CbGdCrCtD
Regorafenib—Hypomagnesaemia—Epirubicin—bone cancer	0.000496	0.00936	CcSEcCtD
Regorafenib—Nail disorder—Epirubicin—bone cancer	0.000485	0.00917	CcSEcCtD
Regorafenib—Polyp—Doxorubicin—bone cancer	0.000479	0.00904	CcSEcCtD
Regorafenib—TEK—connective tissue—bone cancer	0.000478	0.0223	CbGeAlD
Regorafenib—BRAF—tendon—bone cancer	0.000475	0.0221	CbGeAlD
Regorafenib—Cyst—Epirubicin—bone cancer	0.000471	0.00889	CcSEcCtD
Regorafenib—FLT1—connective tissue—bone cancer	0.000463	0.0215	CbGeAlD
Regorafenib—ABL1—Epirubicin—Doxorubicin—bone cancer	0.00046	0.16	CbGdCrCtD
Regorafenib—ABL1—Idarubicin—Doxorubicin—bone cancer	0.00046	0.16	CbGdCrCtD
Regorafenib—ABL1—Daunorubicin—Doxorubicin—bone cancer	0.00046	0.16	CbGdCrCtD
Regorafenib—RAF1—connective tissue—bone cancer	0.00046	0.0214	CbGeAlD
Regorafenib—BRAF—bone marrow—bone cancer	0.00046	0.0214	CbGeAlD
Regorafenib—Hypomagnesaemia—Doxorubicin—bone cancer	0.000459	0.00866	CcSEcCtD
Regorafenib—EPHX2—tendon—bone cancer	0.000453	0.0211	CbGeAlD
Regorafenib—Nail disorder—Doxorubicin—bone cancer	0.000449	0.00848	CcSEcCtD
Regorafenib—Hyponatraemia—Cisplatin—bone cancer	0.000447	0.00844	CcSEcCtD
Regorafenib—Cyst—Doxorubicin—bone cancer	0.000436	0.00823	CcSEcCtD
Regorafenib—Hepatotoxicity—Methotrexate—bone cancer	0.000436	0.00823	CcSEcCtD
Regorafenib—PDGFRA—connective tissue—bone cancer	0.000434	0.0202	CbGeAlD
Regorafenib—Hypokalaemia—Cisplatin—bone cancer	0.000405	0.00765	CcSEcCtD
Regorafenib—FGFR1—tendon—bone cancer	0.000403	0.0188	CbGeAlD
Regorafenib—Aspartate aminotransferase increased—Cisplatin—bone cancer	0.000401	0.00757	CcSEcCtD
Regorafenib—FLT4—bone marrow—bone cancer	0.000396	0.0184	CbGeAlD
Regorafenib—KDR—connective tissue—bone cancer	0.000391	0.0182	CbGeAlD
Regorafenib—FGFR1—spinal cord—bone cancer	0.000389	0.0181	CbGeAlD
Regorafenib—Proteinuria—Methotrexate—bone cancer	0.000383	0.00723	CcSEcCtD
Regorafenib—Dysphonia—Epirubicin—bone cancer	0.000383	0.00723	CcSEcCtD
Regorafenib—Protein urine present—Methotrexate—bone cancer	0.000378	0.00713	CcSEcCtD
Regorafenib—Musculoskeletal stiffness—Methotrexate—bone cancer	0.000375	0.00708	CcSEcCtD
Regorafenib—Liver injury—Epirubicin—bone cancer	0.000374	0.00707	CcSEcCtD
Regorafenib—Hyperbilirubinaemia—Methotrexate—bone cancer	0.00037	0.00699	CcSEcCtD
Regorafenib—Hyperuricaemia—Methotrexate—bone cancer	0.000363	0.00685	CcSEcCtD
Regorafenib—RET—tendon—bone cancer	0.000361	0.0168	CbGeAlD
Regorafenib—Dysphonia—Doxorubicin—bone cancer	0.000354	0.00669	CcSEcCtD
Regorafenib—RET—spinal cord—bone cancer	0.000348	0.0162	CbGeAlD
Regorafenib—KIT—connective tissue—bone cancer	0.000347	0.0161	CbGeAlD
Regorafenib—Hyperbilirubinaemia—Epirubicin—bone cancer	0.000346	0.00654	CcSEcCtD
Regorafenib—Liver injury—Doxorubicin—bone cancer	0.000346	0.00654	CcSEcCtD
Regorafenib—Hypocalcaemia—Epirubicin—bone cancer	0.000344	0.00649	CcSEcCtD
Regorafenib—Blood uric acid increased—Methotrexate—bone cancer	0.000343	0.00647	CcSEcCtD
Regorafenib—Hyperuricaemia—Epirubicin—bone cancer	0.000339	0.00641	CcSEcCtD
Regorafenib—PDGFRB—connective tissue—bone cancer	0.000338	0.0157	CbGeAlD
Regorafenib—Acute coronary syndrome—Cisplatin—bone cancer	0.000338	0.00638	CcSEcCtD
Regorafenib—EPHA2—tendon—bone cancer	0.000337	0.0157	CbGeAlD
Regorafenib—Myocardial infarction—Cisplatin—bone cancer	0.000336	0.00635	CcSEcCtD
Regorafenib—Stomatitis—Cisplatin—bone cancer	0.000334	0.00631	CcSEcCtD
Regorafenib—FGFR2—spinal cord—bone cancer	0.000331	0.0154	CbGeAlD
Regorafenib—TEK—tendon—bone cancer	0.000329	0.0153	CbGeAlD
Regorafenib—Hepatobiliary disease—Cisplatin—bone cancer	0.000324	0.00612	CcSEcCtD
Regorafenib—Blood uric acid increased—Epirubicin—bone cancer	0.000321	0.00605	CcSEcCtD
Regorafenib—Hyperbilirubinaemia—Doxorubicin—bone cancer	0.00032	0.00605	CcSEcCtD
Regorafenib—Hypocalcaemia—Doxorubicin—bone cancer	0.000318	0.00601	CcSEcCtD
Regorafenib—FLT1—tendon—bone cancer	0.000318	0.0148	CbGeAlD
Regorafenib—TEK—spinal cord—bone cancer	0.000317	0.0148	CbGeAlD
Regorafenib—RAF1—tendon—bone cancer	0.000316	0.0147	CbGeAlD
Regorafenib—Hyperuricaemia—Doxorubicin—bone cancer	0.000314	0.00593	CcSEcCtD
Regorafenib—FLT1—spinal cord—bone cancer	0.000307	0.0143	CbGeAlD
Regorafenib—RAF1—bone marrow—bone cancer	0.000306	0.0142	CbGeAlD
Regorafenib—RAF1—spinal cord—bone cancer	0.000305	0.0142	CbGeAlD
Regorafenib—Neoplasm—Methotrexate—bone cancer	0.000304	0.00574	CcSEcCtD
Regorafenib—Urinary tract disorder—Cisplatin—bone cancer	0.000304	0.00574	CcSEcCtD
Regorafenib—Connective tissue disorder—Cisplatin—bone cancer	0.000303	0.00571	CcSEcCtD
Regorafenib—Urethral disorder—Cisplatin—bone cancer	0.000302	0.0057	CcSEcCtD
Regorafenib—ABL1—connective tissue—bone cancer	0.000302	0.014	CbGeAlD
Regorafenib—PDGFRA—tendon—bone cancer	0.000298	0.0139	CbGeAlD
Regorafenib—Blood uric acid increased—Doxorubicin—bone cancer	0.000297	0.0056	CcSEcCtD
Regorafenib—PDGFRA—spinal cord—bone cancer	0.000287	0.0134	CbGeAlD
Regorafenib—Cardiac disorder—Cisplatin—bone cancer	0.000286	0.0054	CcSEcCtD
Regorafenib—Neoplasm—Epirubicin—bone cancer	0.000285	0.00538	CcSEcCtD
Regorafenib—Mediastinal disorder—Cisplatin—bone cancer	0.000278	0.00524	CcSEcCtD
Regorafenib—Alopecia—Cisplatin—bone cancer	0.000272	0.00514	CcSEcCtD
Regorafenib—KDR—tendon—bone cancer	0.000269	0.0125	CbGeAlD
Regorafenib—Malnutrition—Cisplatin—bone cancer	0.000268	0.00506	CcSEcCtD
Regorafenib—Neoplasm—Doxorubicin—bone cancer	0.000263	0.00497	CcSEcCtD
Regorafenib—KDR—bone marrow—bone cancer	0.00026	0.0121	CbGeAlD
Regorafenib—KDR—spinal cord—bone cancer	0.000259	0.0121	CbGeAlD
Regorafenib—Tremor—Cisplatin—bone cancer	0.000251	0.00474	CcSEcCtD
Regorafenib—Anaemia—Cisplatin—bone cancer	0.000248	0.00468	CcSEcCtD
Regorafenib—Leukopenia—Cisplatin—bone cancer	0.00024	0.00453	CcSEcCtD
Regorafenib—PDGFRB—tendon—bone cancer	0.000233	0.0108	CbGeAlD
Regorafenib—KIT—bone marrow—bone cancer	0.000231	0.0107	CbGeAlD
Regorafenib—KIT—spinal cord—bone cancer	0.00023	0.0107	CbGeAlD
Regorafenib—Hyponatraemia—Epirubicin—bone cancer	0.000229	0.00433	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000227	0.00428	CcSEcCtD
Regorafenib—PDGFRB—bone marrow—bone cancer	0.000225	0.0105	CbGeAlD
Regorafenib—PDGFRB—spinal cord—bone cancer	0.000224	0.0104	CbGeAlD
Regorafenib—Toxic epidermal necrolysis—Methotrexate—bone cancer	0.00022	0.00415	CcSEcCtD
Regorafenib—Infection—Cisplatin—bone cancer	0.000217	0.0041	CcSEcCtD
Regorafenib—Nervous system disorder—Cisplatin—bone cancer	0.000215	0.00405	CcSEcCtD
Regorafenib—Thrombocytopenia—Cisplatin—bone cancer	0.000214	0.00404	CcSEcCtD
Regorafenib—Skin disorder—Cisplatin—bone cancer	0.000212	0.00401	CcSEcCtD
Regorafenib—Hyponatraemia—Doxorubicin—bone cancer	0.000212	0.00401	CcSEcCtD
Regorafenib—Dry skin—Epirubicin—bone cancer	0.00021	0.00396	CcSEcCtD
Regorafenib—Hypokalaemia—Epirubicin—bone cancer	0.000208	0.00393	CcSEcCtD
Regorafenib—ABL1—tendon—bone cancer	0.000207	0.00964	CbGeAlD
Regorafenib—Toxic epidermal necrolysis—Epirubicin—bone cancer	0.000206	0.00389	CcSEcCtD
Regorafenib—Aspartate aminotransferase increased—Epirubicin—bone cancer	0.000206	0.00389	CcSEcCtD
Regorafenib—Alanine aminotransferase increased—Epirubicin—bone cancer	0.000202	0.00381	CcSEcCtD
Regorafenib—ABL1—bone marrow—bone cancer	0.000201	0.00934	CbGeAlD
Regorafenib—ABL1—spinal cord—bone cancer	0.0002	0.0093	CbGeAlD
Regorafenib—Neutropenia—Methotrexate—bone cancer	0.000197	0.00373	CcSEcCtD
Regorafenib—Dry skin—Doxorubicin—bone cancer	0.000194	0.00366	CcSEcCtD
Regorafenib—Hypokalaemia—Doxorubicin—bone cancer	0.000192	0.00363	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Doxorubicin—bone cancer	0.00019	0.0036	CcSEcCtD
Regorafenib—Aspartate aminotransferase increased—Doxorubicin—bone cancer	0.00019	0.0036	CcSEcCtD
Regorafenib—Decreased appetite—Cisplatin—bone cancer	0.00019	0.00359	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Cisplatin—bone cancer	0.000189	0.00357	CcSEcCtD
Regorafenib—Infestation NOS—Methotrexate—bone cancer	0.000188	0.00355	CcSEcCtD
Regorafenib—Infestation—Methotrexate—bone cancer	0.000188	0.00355	CcSEcCtD
Regorafenib—Pain—Cisplatin—bone cancer	0.000187	0.00353	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.000187	0.00352	CcSEcCtD
Regorafenib—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.000187	0.00352	CcSEcCtD
Regorafenib—Neutropenia—Epirubicin—bone cancer	0.000185	0.00349	CcSEcCtD
Regorafenib—Stomatitis—Methotrexate—bone cancer	0.000183	0.00346	CcSEcCtD
Regorafenib—Weight decreased—Epirubicin—bone cancer	0.000179	0.00337	CcSEcCtD
Regorafenib—Hepatobiliary disease—Methotrexate—bone cancer	0.000178	0.00336	CcSEcCtD
Regorafenib—Infestation NOS—Epirubicin—bone cancer	0.000176	0.00333	CcSEcCtD
Regorafenib—Infestation—Epirubicin—bone cancer	0.000176	0.00333	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000175	0.0033	CcSEcCtD
Regorafenib—Body temperature increased—Cisplatin—bone cancer	0.000173	0.00327	CcSEcCtD
Regorafenib—Stomatitis—Epirubicin—bone cancer	0.000172	0.00324	CcSEcCtD
Regorafenib—Neutropenia—Doxorubicin—bone cancer	0.000171	0.00323	CcSEcCtD
Regorafenib—Haemoglobin—Methotrexate—bone cancer	0.00017	0.00321	CcSEcCtD
Regorafenib—Haemorrhage—Methotrexate—bone cancer	0.000169	0.00319	CcSEcCtD
Regorafenib—Urinary tract disorder—Methotrexate—bone cancer	0.000167	0.00315	CcSEcCtD
Regorafenib—Hepatobiliary disease—Epirubicin—bone cancer	0.000167	0.00315	CcSEcCtD
Regorafenib—Urethral disorder—Methotrexate—bone cancer	0.000166	0.00313	CcSEcCtD
Regorafenib—Weight decreased—Doxorubicin—bone cancer	0.000165	0.00312	CcSEcCtD
Regorafenib—Infestation NOS—Doxorubicin—bone cancer	0.000163	0.00308	CcSEcCtD
Regorafenib—Infestation—Doxorubicin—bone cancer	0.000163	0.00308	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000162	0.00305	CcSEcCtD
Regorafenib—Erythema multiforme—Methotrexate—bone cancer	0.00016	0.00302	CcSEcCtD
Regorafenib—Haemoglobin—Epirubicin—bone cancer	0.000159	0.003	CcSEcCtD
Regorafenib—Stomatitis—Doxorubicin—bone cancer	0.000159	0.003	CcSEcCtD
Regorafenib—Haemorrhage—Epirubicin—bone cancer	0.000158	0.00299	CcSEcCtD
Regorafenib—Asthenia—Cisplatin—bone cancer	0.000157	0.00296	CcSEcCtD
Regorafenib—Cardiac disorder—Methotrexate—bone cancer	0.000157	0.00296	CcSEcCtD
Regorafenib—Urinary tract disorder—Epirubicin—bone cancer	0.000156	0.00295	CcSEcCtD
Regorafenib—Connective tissue disorder—Epirubicin—bone cancer	0.000155	0.00293	CcSEcCtD
Regorafenib—Urethral disorder—Epirubicin—bone cancer	0.000155	0.00293	CcSEcCtD
Regorafenib—Hepatobiliary disease—Doxorubicin—bone cancer	0.000154	0.00291	CcSEcCtD
Regorafenib—Angiopathy—Methotrexate—bone cancer	0.000153	0.00289	CcSEcCtD
Regorafenib—Mediastinal disorder—Methotrexate—bone cancer	0.000152	0.00288	CcSEcCtD
Regorafenib—Diarrhoea—Cisplatin—bone cancer	0.00015	0.00283	CcSEcCtD
Regorafenib—Erythema multiforme—Epirubicin—bone cancer	0.00015	0.00282	CcSEcCtD
Regorafenib—Alopecia—Methotrexate—bone cancer	0.000149	0.00282	CcSEcCtD
Regorafenib—Malnutrition—Methotrexate—bone cancer	0.000147	0.00278	CcSEcCtD
Regorafenib—Haemoglobin—Doxorubicin—bone cancer	0.000147	0.00278	CcSEcCtD
Regorafenib—Cardiac disorder—Epirubicin—bone cancer	0.000147	0.00277	CcSEcCtD
Regorafenib—Haemorrhage—Doxorubicin—bone cancer	0.000146	0.00276	CcSEcCtD
Regorafenib—Urinary tract disorder—Doxorubicin—bone cancer	0.000144	0.00273	CcSEcCtD
Regorafenib—Connective tissue disorder—Doxorubicin—bone cancer	0.000144	0.00271	CcSEcCtD
Regorafenib—Angiopathy—Epirubicin—bone cancer	0.000143	0.00271	CcSEcCtD
Regorafenib—Urethral disorder—Doxorubicin—bone cancer	0.000143	0.00271	CcSEcCtD
Regorafenib—Mediastinal disorder—Epirubicin—bone cancer	0.000143	0.00269	CcSEcCtD
Regorafenib—Alopecia—Epirubicin—bone cancer	0.00014	0.00264	CcSEcCtD
Regorafenib—Vomiting—Cisplatin—bone cancer	0.000139	0.00263	CcSEcCtD
Regorafenib—Erythema multiforme—Doxorubicin—bone cancer	0.000138	0.00261	CcSEcCtD
Regorafenib—Rash—Cisplatin—bone cancer	0.000138	0.0026	CcSEcCtD
Regorafenib—Dermatitis—Cisplatin—bone cancer	0.000138	0.0026	CcSEcCtD
Regorafenib—Malnutrition—Epirubicin—bone cancer	0.000138	0.0026	CcSEcCtD
Regorafenib—Anaemia—Methotrexate—bone cancer	0.000136	0.00257	CcSEcCtD
Regorafenib—Cardiac disorder—Doxorubicin—bone cancer	0.000136	0.00256	CcSEcCtD
Regorafenib—Angiopathy—Doxorubicin—bone cancer	0.000133	0.00251	CcSEcCtD
Regorafenib—Mediastinal disorder—Doxorubicin—bone cancer	0.000132	0.00249	CcSEcCtD
Regorafenib—Leukopenia—Methotrexate—bone cancer	0.000132	0.00249	CcSEcCtD
Regorafenib—Nausea—Cisplatin—bone cancer	0.00013	0.00245	CcSEcCtD
Regorafenib—Alopecia—Doxorubicin—bone cancer	0.000129	0.00244	CcSEcCtD
Regorafenib—Malnutrition—Doxorubicin—bone cancer	0.000127	0.0024	CcSEcCtD
Regorafenib—Anaemia—Epirubicin—bone cancer	0.000127	0.0024	CcSEcCtD
Regorafenib—ABCG2—bone marrow—bone cancer	0.000127	0.00589	CbGeAlD
Regorafenib—ABCG2—spinal cord—bone cancer	0.000126	0.00586	CbGeAlD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000124	0.00235	CcSEcCtD
Regorafenib—Leukopenia—Epirubicin—bone cancer	0.000123	0.00233	CcSEcCtD
Regorafenib—Infection—Methotrexate—bone cancer	0.000119	0.00225	CcSEcCtD
Regorafenib—Hypertension—Epirubicin—bone cancer	0.000119	0.00224	CcSEcCtD
Regorafenib—Nervous system disorder—Methotrexate—bone cancer	0.000118	0.00222	CcSEcCtD
Regorafenib—Anaemia—Doxorubicin—bone cancer	0.000118	0.00222	CcSEcCtD
Regorafenib—Thrombocytopenia—Methotrexate—bone cancer	0.000118	0.00222	CcSEcCtD
Regorafenib—Skin disorder—Methotrexate—bone cancer	0.000117	0.0022	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000116	0.0022	CcSEcCtD
Regorafenib—Dry mouth—Epirubicin—bone cancer	0.000115	0.00216	CcSEcCtD
Regorafenib—Leukopenia—Doxorubicin—bone cancer	0.000114	0.00215	CcSEcCtD
Regorafenib—Infection—Epirubicin—bone cancer	0.000112	0.00211	CcSEcCtD
Regorafenib—Nervous system disorder—Epirubicin—bone cancer	0.00011	0.00208	CcSEcCtD
Regorafenib—Thrombocytopenia—Epirubicin—bone cancer	0.00011	0.00208	CcSEcCtD
Regorafenib—Hypertension—Doxorubicin—bone cancer	0.00011	0.00208	CcSEcCtD
Regorafenib—Skin disorder—Epirubicin—bone cancer	0.000109	0.00206	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000108	0.00203	CcSEcCtD
Regorafenib—Dry mouth—Doxorubicin—bone cancer	0.000106	0.002	CcSEcCtD
Regorafenib—Decreased appetite—Methotrexate—bone cancer	0.000104	0.00197	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Methotrexate—bone cancer	0.000104	0.00196	CcSEcCtD
Regorafenib—Fatigue—Methotrexate—bone cancer	0.000103	0.00195	CcSEcCtD
Regorafenib—Infection—Doxorubicin—bone cancer	0.000103	0.00195	CcSEcCtD
Regorafenib—Pain—Methotrexate—bone cancer	0.000103	0.00194	CcSEcCtD
Regorafenib—Nervous system disorder—Doxorubicin—bone cancer	0.000102	0.00192	CcSEcCtD
Regorafenib—Thrombocytopenia—Doxorubicin—bone cancer	0.000102	0.00192	CcSEcCtD
Regorafenib—Skin disorder—Doxorubicin—bone cancer	0.000101	0.00191	CcSEcCtD
Regorafenib—Gastrointestinal pain—Methotrexate—bone cancer	9.82e-05	0.00185	CcSEcCtD
Regorafenib—Decreased appetite—Epirubicin—bone cancer	9.77e-05	0.00184	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Epirubicin—bone cancer	9.7e-05	0.00183	CcSEcCtD
Regorafenib—Fatigue—Epirubicin—bone cancer	9.69e-05	0.00183	CcSEcCtD
Regorafenib—Pain—Epirubicin—bone cancer	9.61e-05	0.00181	CcSEcCtD
Regorafenib—Abdominal pain—Methotrexate—bone cancer	9.49e-05	0.00179	CcSEcCtD
Regorafenib—Body temperature increased—Methotrexate—bone cancer	9.49e-05	0.00179	CcSEcCtD
Regorafenib—Gastrointestinal pain—Epirubicin—bone cancer	9.19e-05	0.00173	CcSEcCtD
Regorafenib—Decreased appetite—Doxorubicin—bone cancer	9.04e-05	0.00171	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Doxorubicin—bone cancer	8.97e-05	0.00169	CcSEcCtD
Regorafenib—Fatigue—Doxorubicin—bone cancer	8.96e-05	0.00169	CcSEcCtD
Regorafenib—Pain—Doxorubicin—bone cancer	8.89e-05	0.00168	CcSEcCtD
Regorafenib—Abdominal pain—Epirubicin—bone cancer	8.88e-05	0.00168	CcSEcCtD
Regorafenib—Body temperature increased—Epirubicin—bone cancer	8.88e-05	0.00168	CcSEcCtD
Regorafenib—Asthenia—Methotrexate—bone cancer	8.61e-05	0.00163	CcSEcCtD
Regorafenib—Gastrointestinal pain—Doxorubicin—bone cancer	8.5e-05	0.0016	CcSEcCtD
Regorafenib—Body temperature increased—Doxorubicin—bone cancer	8.22e-05	0.00155	CcSEcCtD
Regorafenib—Abdominal pain—Doxorubicin—bone cancer	8.22e-05	0.00155	CcSEcCtD
Regorafenib—Diarrhoea—Methotrexate—bone cancer	8.21e-05	0.00155	CcSEcCtD
Regorafenib—Asthenia—Epirubicin—bone cancer	8.06e-05	0.00152	CcSEcCtD
Regorafenib—Diarrhoea—Epirubicin—bone cancer	7.69e-05	0.00145	CcSEcCtD
Regorafenib—Vomiting—Methotrexate—bone cancer	7.63e-05	0.00144	CcSEcCtD
Regorafenib—Rash—Methotrexate—bone cancer	7.57e-05	0.00143	CcSEcCtD
Regorafenib—Dermatitis—Methotrexate—bone cancer	7.56e-05	0.00143	CcSEcCtD
Regorafenib—Headache—Methotrexate—bone cancer	7.52e-05	0.00142	CcSEcCtD
Regorafenib—Asthenia—Doxorubicin—bone cancer	7.46e-05	0.00141	CcSEcCtD
Regorafenib—Vomiting—Epirubicin—bone cancer	7.14e-05	0.00135	CcSEcCtD
Regorafenib—Nausea—Methotrexate—bone cancer	7.13e-05	0.00135	CcSEcCtD
Regorafenib—Diarrhoea—Doxorubicin—bone cancer	7.11e-05	0.00134	CcSEcCtD
Regorafenib—Rash—Epirubicin—bone cancer	7.08e-05	0.00134	CcSEcCtD
Regorafenib—Dermatitis—Epirubicin—bone cancer	7.08e-05	0.00134	CcSEcCtD
Regorafenib—Headache—Epirubicin—bone cancer	7.04e-05	0.00133	CcSEcCtD
Regorafenib—Nausea—Epirubicin—bone cancer	6.67e-05	0.00126	CcSEcCtD
Regorafenib—Vomiting—Doxorubicin—bone cancer	6.61e-05	0.00125	CcSEcCtD
Regorafenib—Rash—Doxorubicin—bone cancer	6.55e-05	0.00124	CcSEcCtD
Regorafenib—Dermatitis—Doxorubicin—bone cancer	6.55e-05	0.00124	CcSEcCtD
Regorafenib—Headache—Doxorubicin—bone cancer	6.51e-05	0.00123	CcSEcCtD
Regorafenib—ABCB1—bone marrow—bone cancer	6.25e-05	0.0029	CbGeAlD
Regorafenib—ABCB1—spinal cord—bone cancer	6.22e-05	0.00289	CbGeAlD
Regorafenib—Nausea—Doxorubicin—bone cancer	6.17e-05	0.00117	CcSEcCtD
Regorafenib—KIT—Signaling Pathways—IL3—bone cancer	1.17e-05	9.29e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—MDM2—bone cancer	1.17e-05	9.29e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—ATF1—bone cancer	1.14e-05	9.04e-05	CbGpPWpGaD
Regorafenib—ABL1—Developmental Biology—MMP9—bone cancer	1.13e-05	9.02e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—ATF1—bone cancer	1.13e-05	9.02e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—IL3—bone cancer	1.11e-05	8.82e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—TGFBR2—bone cancer	1.11e-05	8.81e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—IL3—bone cancer	1.1e-05	8.8e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—GNA11—bone cancer	1.1e-05	8.74e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—TGFBR2—bone cancer	1.1e-05	8.73e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—DHFR—bone cancer	1.09e-05	8.69e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—CYP3A4—bone cancer	1.09e-05	8.68e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—CYP3A4—bone cancer	1.09e-05	8.68e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.08e-05	8.64e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—TGFBR2—bone cancer	1.08e-05	8.63e-05	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—MDM2—bone cancer	1.08e-05	8.62e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—NDUFA12—bone cancer	1.08e-05	8.6e-05	CbGpPWpGaD
Regorafenib—MAPK11—Innate Immune System—EGFR—bone cancer	1.08e-05	8.59e-05	CbGpPWpGaD
Regorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	1.07e-05	8.56e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—KIT—bone cancer	1.07e-05	8.54e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—SMO—bone cancer	1.07e-05	8.52e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—KIT—bone cancer	1.07e-05	8.51e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—JUN—bone cancer	1.06e-05	8.41e-05	CbGpPWpGaD
Regorafenib—FGFR1—Developmental Biology—EGFR—bone cancer	1.05e-05	8.33e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—IGF1R—bone cancer	1.04e-05	8.29e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—MDM2—bone cancer	1.04e-05	8.28e-05	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—MDM2—bone cancer	1.04e-05	8.28e-05	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—MMP9—bone cancer	1.04e-05	8.25e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—IGF1R—bone cancer	1.03e-05	8.21e-05	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—JUN—bone cancer	1.03e-05	8.19e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—GNA11—bone cancer	1.02e-05	8.13e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—ATF1—bone cancer	1.02e-05	8.13e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—TGFBR2—bone cancer	1.02e-05	8.09e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—KIT—bone cancer	9.99e-06	7.96e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—TGFBR2—bone cancer	9.98e-06	7.95e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—KIT—bone cancer	9.97e-06	7.94e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IL3—bone cancer	9.95e-06	7.92e-05	CbGpPWpGaD
Regorafenib—FGFR2—Innate Immune System—EGFR—bone cancer	9.91e-06	7.89e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—KIT—bone cancer	9.9e-06	7.88e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—GNA11—bone cancer	9.78e-06	7.79e-05	CbGpPWpGaD
Regorafenib—KIT—Innate Immune System—EGFR—bone cancer	9.73e-06	7.75e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—IGF1R—bone cancer	9.56e-06	7.61e-05	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—EGFR—bone cancer	9.52e-06	7.58e-05	CbGpPWpGaD
Regorafenib—FGFR2—Adaptive Immune System—EGFR—bone cancer	9.52e-06	7.58e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—TGFBR2—bone cancer	9.47e-06	7.54e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—TGFBR2—bone cancer	9.45e-06	7.52e-05	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—JUN—bone cancer	9.41e-06	7.49e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—IGF1R—bone cancer	9.39e-06	7.48e-05	CbGpPWpGaD
Regorafenib—KIT—Adaptive Immune System—EGFR—bone cancer	9.34e-06	7.44e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—GSTP1—bone cancer	9.32e-06	7.43e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—GSTP1—bone cancer	9.32e-06	7.43e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—BRAF—bone cancer	9.31e-06	7.41e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—KIT—bone cancer	9.29e-06	7.4e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—CYP3A4—bone cancer	9.25e-06	7.37e-05	CbGpPWpGaD
Regorafenib—FGFR1—Innate Immune System—EGFR—bone cancer	9.24e-06	7.35e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—KIT—bone cancer	9.23e-06	7.35e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Innate Immune System—EGFR—bone cancer	9.21e-06	7.34e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—KIT—bone cancer	9.2e-06	7.33e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—MDM2—bone cancer	9.2e-06	7.33e-05	CbGpPWpGaD
Regorafenib—ABL1—Developmental Biology—EGFR—bone cancer	9.16e-06	7.29e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—BRAF—bone cancer	9.14e-06	7.28e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—ATF1—bone cancer	9.09e-06	7.24e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—JUN—bone cancer	9.03e-06	7.19e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—KIT—bone cancer	8.98e-06	7.15e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—NT5C3A—bone cancer	8.95e-06	7.13e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—IGF1R—bone cancer	8.91e-06	7.1e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—IGF1R—bone cancer	8.89e-06	7.08e-05	CbGpPWpGaD
Regorafenib—FGFR1—Adaptive Immune System—EGFR—bone cancer	8.87e-06	7.06e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IL3—bone cancer	8.87e-06	7.06e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Adaptive Immune System—EGFR—bone cancer	8.85e-06	7.04e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—MMP9—bone cancer	8.79e-06	7e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—KIT—bone cancer	8.78e-06	6.99e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—KIT—bone cancer	8.75e-06	6.97e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—BRAF—bone cancer	8.73e-06	6.96e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—BRAF—bone cancer	8.67e-06	6.91e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—BRAF—bone cancer	8.65e-06	6.89e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—ENO2—bone cancer	8.63e-06	6.87e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—TGFBR2—bone cancer	8.51e-06	6.78e-05	CbGpPWpGaD
Regorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	8.45e-06	6.73e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—MDM2—bone cancer	8.45e-06	6.73e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—MDM2—bone cancer	8.41e-06	6.7e-05	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—EGFR—bone cancer	8.38e-06	6.67e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—EGFR—bone cancer	8.3e-06	6.61e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—MDM2—bone cancer	8.29e-06	6.61e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—KIT—bone cancer	8.29e-06	6.6e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—BRAF—bone cancer	8.25e-06	6.57e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—PTGS2—bone cancer	8.11e-06	6.46e-05	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—EGFR—bone cancer	8.09e-06	6.44e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IGF1R—bone cancer	8.01e-06	6.38e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—KIT—bone cancer	8.01e-06	6.37e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—DHFR—bone cancer	8e-06	6.37e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—JUN—bone cancer	8e-06	6.37e-05	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—TP53—bone cancer	7.99e-06	6.37e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—EGFR—bone cancer	7.97e-06	6.35e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—GSTP1—bone cancer	7.91e-06	6.3e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—MDM2—bone cancer	7.87e-06	6.27e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—MDM2—bone cancer	7.85e-06	6.25e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—MDM2—bone cancer	7.8e-06	6.21e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—BRAF—bone cancer	7.79e-06	6.21e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—MDM2—bone cancer	7.66e-06	6.1e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—TGFBR2—bone cancer	7.58e-06	6.04e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—KIT—bone cancer	7.55e-06	6.01e-05	CbGpPWpGaD
Regorafenib—ABL1—Hemostasis—TP53—bone cancer	7.54e-06	6.01e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—PTGS2—bone cancer	7.52e-06	5.99e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—KIT—bone cancer	7.48e-06	5.96e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—GNA11—bone cancer	7.48e-06	5.96e-05	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—EGFR—bone cancer	7.4e-06	5.89e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—KIT—bone cancer	7.39e-06	5.89e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—PTGS2—bone cancer	7.38e-06	5.88e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—JUN—bone cancer	7.34e-06	5.85e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—MDM2—bone cancer	7.32e-06	5.83e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—ENO2—bone cancer	7.3e-06	5.82e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—MDM2—bone cancer	7.27e-06	5.79e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—MDM2—bone cancer	7.25e-06	5.77e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—JUN—bone cancer	7.21e-06	5.74e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IGF1R—bone cancer	7.14e-06	5.68e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—EGFR—bone cancer	7.1e-06	5.66e-05	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—EGFR—bone cancer	7.1e-06	5.66e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—BRAF—bone cancer	7.1e-06	5.65e-05	CbGpPWpGaD
Regorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	7.09e-06	5.65e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—MDM2—bone cancer	7.07e-06	5.63e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—PTGS2—bone cancer	7.01e-06	5.58e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—PTGS2—bone cancer	6.99e-06	5.57e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—BRAF—bone cancer	6.95e-06	5.53e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—KIT—bone cancer	6.93e-06	5.52e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—MDM2—bone cancer	6.92e-06	5.51e-05	CbGpPWpGaD
Regorafenib—RAF1—Hemostasis—TP53—bone cancer	6.9e-06	5.49e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—MDM2—bone cancer	6.89e-06	5.49e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—JUN—bone cancer	6.84e-06	5.45e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—JUN—bone cancer	6.82e-06	5.43e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—CYP3A4—bone cancer	6.78e-06	5.4e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—DHFR—bone cancer	6.78e-06	5.4e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—MDM2—bone cancer	6.53e-06	5.2e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—ENO2—bone cancer	6.52e-06	5.19e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—BRAF—bone cancer	6.52e-06	5.19e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—KIT—bone cancer	6.46e-06	5.15e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—KIT—bone cancer	6.45e-06	5.13e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—BRAF—bone cancer	6.4e-06	5.1e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—ENO2—bone cancer	6.36e-06	5.07e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—JUN—bone cancer	6.36e-06	5.07e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—GNA11—bone cancer	6.33e-06	5.04e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—MDM2—bone cancer	6.3e-06	5.02e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—PTGS2—bone cancer	6.3e-06	5.01e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—EGFR—bone cancer	6.29e-06	5.01e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—MMP9—bone cancer	6.19e-06	4.93e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—JUN—bone cancer	6.15e-06	4.9e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—BRAF—bone cancer	6.07e-06	4.84e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—BRAF—bone cancer	6.06e-06	4.82e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—DHFR—bone cancer	6.05e-06	4.82e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—JUN—bone cancer	6.01e-06	4.79e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—JUN—bone cancer	5.99e-06	4.77e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—TP53—bone cancer	5.96e-06	4.75e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—MDM2—bone cancer	5.95e-06	4.74e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ENO2—bone cancer	5.94e-06	4.73e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—DHFR—bone cancer	5.9e-06	4.7e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—MDM2—bone cancer	5.89e-06	4.69e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—MMP9—bone cancer	5.85e-06	4.66e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—MDM2—bone cancer	5.82e-06	4.64e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—KIT—bone cancer	5.81e-06	4.62e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—GSTP1—bone cancer	5.8e-06	4.62e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—EGFR—bone cancer	5.77e-06	4.6e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—EGFR—bone cancer	5.75e-06	4.58e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—CYP3A4—bone cancer	5.74e-06	4.57e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	5.71e-06	4.55e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—EGFR—bone cancer	5.67e-06	4.51e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—GNA11—bone cancer	5.65e-06	4.5e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—PTGS2—bone cancer	5.61e-06	4.47e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—GNA11—bone cancer	5.52e-06	4.39e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—DHFR—bone cancer	5.51e-06	4.39e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—JUN—bone cancer	5.48e-06	4.36e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—MDM2—bone cancer	5.46e-06	4.35e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—BRAF—bone cancer	5.46e-06	4.35e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—EGFR—bone cancer	5.38e-06	4.28e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—EGFR—bone cancer	5.37e-06	4.27e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—MDM2—bone cancer	5.36e-06	4.27e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—EGFR—bone cancer	5.33e-06	4.24e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—EGFR—bone cancer	5.23e-06	4.17e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—KIT—bone cancer	5.18e-06	4.12e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—JUN—bone cancer	5.17e-06	4.12e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—GNA11—bone cancer	5.15e-06	4.1e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—CYP3A4—bone cancer	5.12e-06	4.08e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—JUN—bone cancer	5.12e-06	4.08e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	5.1e-06	4.06e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MDM2—bone cancer	5.09e-06	4.05e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MDM2—bone cancer	5.08e-06	4.04e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—MMP9—bone cancer	5.03e-06	4.01e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—CYP3A4—bone cancer	5e-06	3.98e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—EGFR—bone cancer	5e-06	3.98e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—MMP9—bone cancer	4.98e-06	3.97e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—EGFR—bone cancer	4.97e-06	3.96e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—EGFR—bone cancer	4.95e-06	3.94e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—GSTP1—bone cancer	4.91e-06	3.91e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—BRAF—bone cancer	4.86e-06	3.87e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—EGFR—bone cancer	4.83e-06	3.85e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—PTGS2—bone cancer	4.83e-06	3.85e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—PTGS2—bone cancer	4.83e-06	3.85e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—JUN—bone cancer	4.75e-06	3.78e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—EGFR—bone cancer	4.73e-06	3.76e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—EGFR—bone cancer	4.72e-06	3.76e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—EGFR—bone cancer	4.71e-06	3.75e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CYP3A4—bone cancer	4.67e-06	3.72e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—JUN—bone cancer	4.66e-06	3.71e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4.65e-06	3.7e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—MMP9—bone cancer	4.62e-06	3.68e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MDM2—bone cancer	4.57e-06	3.64e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—MMP9—bone cancer	4.53e-06	3.61e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—EGFR—bone cancer	4.46e-06	3.55e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—JUN—bone cancer	4.42e-06	3.52e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—JUN—bone cancer	4.41e-06	3.51e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—GSTP1—bone cancer	4.38e-06	3.49e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—EGFR—bone cancer	4.31e-06	3.43e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MMP9—bone cancer	4.3e-06	3.43e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MMP9—bone cancer	4.29e-06	3.42e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—GSTP1—bone cancer	4.28e-06	3.41e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—TP53—bone cancer	4.2e-06	3.34e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—PTGS2—bone cancer	4.1e-06	3.26e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MDM2—bone cancer	4.08e-06	3.25e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—EGFR—bone cancer	4.06e-06	3.24e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—EGFR—bone cancer	4.03e-06	3.21e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—GSTP1—bone cancer	4e-06	3.18e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—EGFR—bone cancer	3.98e-06	3.17e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—JUN—bone cancer	3.98e-06	3.17e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—TP53—bone cancer	3.97e-06	3.16e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ENO2—bone cancer	3.92e-06	3.12e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MMP9—bone cancer	3.87e-06	3.08e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—EGFR—bone cancer	3.73e-06	2.97e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—EGFR—bone cancer	3.66e-06	2.92e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—DHFR—bone cancer	3.64e-06	2.9e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—JUN—bone cancer	3.54e-06	2.82e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—EGFR—bone cancer	3.48e-06	2.77e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—EGFR—bone cancer	3.47e-06	2.76e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MMP9—bone cancer	3.45e-06	2.75e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—TP53—bone cancer	3.41e-06	2.72e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GNA11—bone cancer	3.4e-06	2.71e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—TP53—bone cancer	3.38e-06	2.69e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—TP53—bone cancer	3.13e-06	2.49e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—EGFR—bone cancer	3.13e-06	2.49e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—TP53—bone cancer	3.08e-06	2.45e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PTGS2—bone cancer	3e-06	2.39e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—TP53—bone cancer	2.92e-06	2.33e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—TP53—bone cancer	2.91e-06	2.32e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—EGFR—bone cancer	2.79e-06	2.22e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GSTP1—bone cancer	2.64e-06	2.1e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—TP53—bone cancer	2.62e-06	2.09e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PTGS2—bone cancer	2.54e-06	2.03e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—TP53—bone cancer	2.34e-06	1.86e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PTGS2—bone cancer	2.27e-06	1.81e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PTGS2—bone cancer	2.22e-06	1.76e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PTGS2—bone cancer	2.07e-06	1.65e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PTGS2—bone cancer	1.37e-06	1.09e-05	CbGpPWpGaD
